Preclinical evidence supports sotagliflozin’s superior efficacy in attenuating salt-induced kidney damage
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In ...